Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q02763
UPID:
TIE2_HUMAN
Alternative names:
Endothelial tyrosine kinase; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; p140 TEK
Alternative UPACC:
Q02763; A8K6W0; B4DH20; B4DHD3; D3DRK5; E7EWI2; Q5TCU2; Q8IV34
Background:
The Angiopoietin-1 receptor, known by names such as Endothelial tyrosine kinase and Tyrosine-protein kinase receptor TEK, plays a pivotal role in angiogenesis and vascular stability. It acts as a cell-surface receptor for ANGPT1, ANGPT2, and ANGPT4, regulating endothelial cell survival, proliferation, and migration. Its function is critical in maintaining vascular quiescence and promoting anti-inflammatory effects by preventing leakage from blood vessels.
Therapeutic significance:
Linked to Dominantly inherited venous malformations and Glaucoma 3, primary congenital, E, the Angiopoietin-1 receptor's involvement in these diseases underscores its potential as a therapeutic target. Understanding its role could open doors to innovative treatments for vascular and ocular disorders.